Abstract. Urine 
l-deamino-8-D-arginine vasopressin (DDAVP, desmopressin) is administered as an intranasal spray to patients with diabetes insipidus (Aronson et al. 1973; Seif et al. 1978) , but is also active after sublingual application (Grossman et al. 1980; Laczi et al. 1980) . Although these routes of administra¬ tion are preferable to injections they are not with¬ out disadvantages. The prospect of delivering the peptides in a peroral form seems attactive, but has received little attention, probably because it is generally believed that peptides are completelydegraded by the intestinal peptidases.
DDAVP dissolved in the drinking water leads to a reduction in urine production in diabetes insi¬ pidus rats (Dunn et al. 1978) , however, this effect could be due to absorption of the peptide from the oral mucosa.
It has recently been demonstrated that vasopressin and DDAVP given by gastric tube to anaesthe¬ tized rats (Saffran et al. 1979) and to conscious dogs (Vilhardt & Bie 1983) (Fig. 2) 
